Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 18 2022 - 11:28AM
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a
clinical stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, today announced the
closing of its previously announced public offering of 22,500,000
common shares, at the public offering price of $4.00 per share, and
the exercise in full by the underwriters of their option to
purchase an additional 3,375,000 common shares. The exercise of the
option to purchase over-allotment shares brought the total number
of common shares sold by Affimed to 25,875,000 common shares and
increased the gross proceeds raised in the offering, before
deducting underwriting discounts and commissions and estimated
expenses of the offering payable by Affimed, to $103.5 million.
Jefferies LLC, SVB Leerink, Truist Securities,
Inc. and Wells Fargo Securities, LLC are acting as joint
book-running managers and Berenberg Capital Markets LLC is acting
as a co-manager of the offering. A shelf registration statement
relating to these securities filed with the Securities and Exchange
Commission (the “SEC”) was declared effective by the SEC on April
6, 2022. The offering was made only by means of a prospectus and
prospectus supplement. A prospectus supplement and accompanying
prospectus related to the offering have been filed with the SEC and
are available at the SEC’s website located at www.sec.gov. Copies
of the prospectus supplement and accompanying prospectus related to
the offering may be obtained by contacting Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388 or by email at Prospectus_Department@Jefferies.com, SVB
Securities LLC, Attn: Syndicate Department, 53 State Street, 40th
Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525,
ext. 6105, or by email at syndicate@svbleerink.com, Truist
Securities, Inc., Attention: Prospectus Department, 3333 Peachtree
Road, NE, 11th Floor, Atlanta, Georgia 30326, by telephone at (800)
685-4786, or by email at TruistSecurities.prospectus@Truist.com, or
Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 500 West 33rd Street, New York, New York 10001, by
telephone at (833) 690-2713, or by email at
cmclientsupport@wellsfargo.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer by actualizing the untapped
potential of the innate immune system. The Company’s proprietary
ROCK® platform enables a tumor-targeted approach to recognize
and kill a range of hematologic and solid tumors, enabling a broad
pipeline of wholly-owned and partnered single agent and combination
therapy programs. The ROCK® platform predictably generates
customized innate cell engager (ICE®) molecules, which use
patients’ immune cells to destroy tumor cells. This innovative
approach enabled Affimed to become the first company with a
clinical-stage ICE®. Headquartered in Heidelberg, Germany, with
offices in New York, NY, Affimed is led by an experienced team of
biotechnology and pharmaceutical leaders united by a bold vision to
stop cancer from ever derailing patients’ lives.
Forward-looking Statements
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed offering of common shares and the anticipated use of
the net proceeds. No assurance can be given that the offering
discussed above will be completed on the terms described, or at
all, or that the net proceeds of the offering will be used as
indicated. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the company,
including those set forth in the Risk Factors section of the
company’s registration statement and preliminary prospectus for the
company’s offering filed with the Securities and Exchange
Commission (“SEC”). Copies are available on the SEC’s website,
www.sec.gov. Given these risks, uncertainties, and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Investor Relations ContactAlexander
FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.com Tel.: +1 (917) 436-8102
Media ContactMary Beth Sandin Vice President,
Marketing and CommunicationsE-Mail: m.sandin@affimed.com Tel: +1
(484) 888-8195
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024